Study on the development of nanoparticles based on levan for oral insulin delivery
Source abstract
Abstract
Abstract Oral insulin administration has gained attention as a promising alternative to injections. However, its effectiveness is hindered by the major challenge of degradation by gastric acid. Biopolymer-based nanocarriers have been explored as a solution to address this challenge. This study examines levan, a biopolymer derived from Bacillus licheniformis BK1, for its viability as a nanocarrier for insulin. Levan was modified through acetylation, and both levan (I-Lv) and its acetylated (I-ALv) form were utilized as carriers for insulin in a nanoparticles (NPs) delivery system. The resulting NPs were spherical, with diameters ranging from 250 to 500 nm and encapsulation efficiencies of 78.64% and 88.30%, respectively. The insulin release from I-Lv NPs in simulated gastric fluid exhibited a burst release pattern that was more rapid than that of I-ALv. To further evaluate, the conformational stability of insulin in NPs was analyzed by measuring the transition enthalpy of secondary and tertiary structures. The stability of the secondary structure was determined through alpha-helix content using circular dichroism, while the tertiary structure stability was evaluated via the fluorescence intensity of tryptophan residues. The result revealed that insulin in I-ALv NPs exhibited enhanced conformational stability compared to free-state (FS) insulin and I-Lv NP, with transition enthalpies of 0.91 ± 0.62 and 4.42 ± 0.46 kcal mol−1 for secondary and tertiary structures, respectively. Moreover, preliminary in vivo studies revealed that I-ALv had a significant impact compared to FS insulin and I-Lv, demonstrating reduction in blood glucose levels. These findings highlight the potential of I-ALv as a promising candidate for antidiabetic therapy and an efficient oral delivery system.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Microbial Metabolites in Food Biotechnology · Diabetes Treatment and Management · Intestinal Malrotation and Obstruction Disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. The diabetes mellitus–atherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation10.3390/ijms21051835 ↗
2. Diabetes mellitus and its metabolic complications: the role of adipose tissues10.3390/ijms22147644 ↗
3. Current practice in the perioperative management of patients with diabetes mellitus: a narrative review10.1016/j.bja.2023.02.039 ↗
4. Transdermal drug delivery systems in diabetes management: a review10.1016/j.ajps.2019.04.006 ↗
5. Insulin therapy for the management of diabetes mellitus: a narrative review of innovative treatment strategies10.1007/s13300-023-01468-4 ↗
6. Nanoparticle based insulin delivery system: the next generation efficient therapy for type 1 diabetes10.1186/s12951-015-0136-y ↗
7. Current advances in the management of diabetes mellitus10.3390/biomedicines10102436 ↗
8. Carboxymethyl β-cyclodextrin grafted carboxymethyl chitosan hydrogel-based microparticles for oral insulin delivery10.1016/j.carbpol.2020.116617 ↗
9. Oral insulin delivery in a physiologic context: review10.1177/1932296817691303 ↗
10. Recent progress of chitosan and chitosan derivatives-based nanoparticles: pharmaceutical perspectives of oral insulin delivery10.3390/ph13100307 ↗
11. Advances in nanomedicine for precision insulin delivery10.3390/ph17070945 ↗
12. Biomedical applications of biodegradable polymers10.1002/polb.22259 ↗
13. Polysaccharides-based nanoparticles as drug delivery systems10.1016/j.addr.2008.09.001 ↗
14. Biopolymeric nanoparticles10.1088/1468-6996/11/1/014104 ↗
15. Preparation and application of micro/nanoparticles based on natural polysaccharides10.1016/j.carbpol.2015.01.029 ↗
16. Review of Levan polysaccharide: from a century of past experiences to future prospects10.1016/j.biotechadv.2016.05.002 ↗
17. Levan production potentials from different hypersaline environments in Turkey10.15414/jmbfs.2020.10.1.61-64 ↗
18. Levan production by Suhomyces kilbournensis using sugarcane molasses as a carbon source in submerged fermentation10.3390/molecules29051105 ↗
19. Co-production of levan with other high-value bioproducts: A review10.1016/j.ijbiomac.2023.123800 ↗
20. Recent developments and applications of microbial levan, a versatile polysaccharide-based biopolymer10.3390/molecules28145407 ↗
21. Development and characterization of vancomycin-loaded levan-based microparticular system for drug delivery10.3109/10837450.2015.1116564 ↗
22. Structural characterization and antioxidant activity of an acetylated Cyclocarya paliurus polysaccharide (Ac-CPP0.1)10.1016/j.ijbiomac.2020.12.201 ↗
23. Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry10.1039/D3RA06476J ↗
24. Factors affecting the physical stability (aggregation) of peptide therapeutics10.1098/rsfs.2017.0030 ↗
25. Development of inulin nanocarrier for effective oral delivery of insulin: synthesize, optimization, characterization, and biophysical study10.1080/09205063.2024.2436297 ↗
26. Thermodynamics of protein denaturation at temperatures over 100 °C: cutA1 mutant proteins substituted with hydrophobic and charged residues10.1038/srep15545 ↗
27. The denaturation and degradation of stable enzymes at high temperatures10.1042/bj3170001 ↗
28. Development of a nanoparticle system based on a fructose polymer: stability and drug release studies10.1016/j.carbpol.2016.12.025 ↗
29. Chemically modified inulin for intestinal drug delivery—a new dual bioactivity concept for inflammatory bowel disease treatment10.1016/j.carbpol.2020.117091 ↗
30. Electrosprayed inulin microparticles for microbiota triggered targeting of colon10.1016/j.carbpol.2014.05.087 ↗
31. Preparation and characterization of inulin ester microspheres as drug carriers10.1002/(SICI)1097-4628(20000725)77:4<833::AID-APP17>3.0.CO;2-4 ↗
32. Statistical characterization of the morphologies of nanoparticles through machine learning based electron microscopy image analysis10.1021/acsnano.0c06809 ↗
33. Formulation development, stability and anticancer efficacy of core-shell cyclodextrin nanocapsules for oral chemotherapy with camptothecin10.3762/bjoc.11.22 ↗
34. Environmental friendly carrier material for nifedipine as hypertension drug10.22034/gjesm.2020.04.08 ↗
35. Phytase immobilization on hydroxyapatite nanoparticles improves its properties for use in animal feed10.1007/s12010-019-03116-9 ↗
36. Nanoparticles with a specific size and surface charge promote disruption of the secondary structure and amyloid-like fibrillation of human insulin under physiological conditions10.3389/fchem.2019.00480 ↗
37. Fermentation parameters and conditions affecting levan production and its potential applications in cosmetics10.1016/j.bioorg.2019.02.012 ↗
38. Levan produced by the halophilic bacterium Bacillus licheniformis BK1 as a nanoparticle for protein immobilization10.22146/ijc.41064 ↗
39. Properties of levan and potential medical uses10.1021/bk-2006-0934.ch013 ↗
40. Natural polysaccharide-based nanodrug delivery systems for treatment of diabetes10.3390/polym14153217 ↗
41. Polysaccharide-based nanoparticles equipped with glucose oxidase for in vivo insulin delivery10.1021/acsanm.4c00210 ↗
42. Optimization of levan production by cold-active bacillus licheniformis ANT 179 and fructooligosaccharide synthesis by its levansucrase10.1007/s12010-016-2264-8 ↗
43. Nanoencapsulation of date palm pit extract in whey protein particles generated via desolvation method10.1016/j.foodres.2013.01.058 ↗
44. Applications of infrared spectroscopy in polysaccharide structural analysis: Progress, challenge and perspective10.1016/j.fochx.2021.100168 ↗
45. Alginate/chitosan nanoparticles are effective for oral insulin delivery10.1007/s11095-007-9367-4 ↗
46. Chemical modification of bacterial exopolysaccharides: antioxidant properties and health potentials10.1016/j.crfs.2024.100824 ↗
47. Preparation, antioxidant and antitumor activities in vitro of different derivatives of levan from endophytic bacterium Paenibacillus polymyxa EJS-310.1016/j.fct.2011.11.016 ↗
48. Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans10.1016/j.biomaterials.2009.03.013 ↗
49. Synthesis and characterization of chitosan nanoparticles decorated with folate and loaded with dasatinib for targeting folate receptors in cancer cells10.1016/j.onano.2022.100043 ↗
50. Effects of particle size distribution on the physicochemical, functional, and structural properties of alfalfa leaf powder10.3390/agriculture14040634 ↗
51. Temperature-responsive polysaccharide microparticles containing nanoparticles: release of multiple cationic/anionic compounds10.3390/ma15134717 ↗
52. Probing insulin’s secondary structure after entrapment into alginate/chitosan nanoparticles10.1016/j.ejpb.2006.09.005 ↗
53. In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms10.1208/s12248-008-9027-6 ↗
54. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations10.1016/S0168-3659(01)00268-1 ↗
55. Amphiphilic lipopeptide-mediated transport of insulin and cell membrane penetration mechanism10.3390/molecules201219771 ↗
56. Tyrosine autofluorescence as a measure of bovine insulin fibrillation10.1016/j.bpj.2009.07.064 ↗